论文部分内容阅读
目的:通过分析癌症基因组图谱（TCGA）数据库，筛选胆管癌预后相关长链非编码RNA（lncRNA）GIHCG，检测其在胆管癌组织中的表达水平，探讨其临床意义。方法:使用R语言的limma包分析TCGA中31例胆管癌组织和9例癌旁组织的数据，后用survival包及survival ROC包筛选与患者生存相关的差异基因表达lncRNA。通过实时荧光定量聚合酶链反应（real-time PCR）和免疫荧光原位杂交技术（FISH）检测lncRNA的表达水平，分析其与患者临床特征的相关性。采用小干扰RNA敲低lncRNA GIHCG表达水平，通过Transwell检测其对胆管癌细胞系迁移能力的影响。结果:共筛选到2 970个差异表达lncRNAs，其中上调1 852个，下调1 118个。生存分析、受试者工作特征（ROC）曲线［显示lncRNA GIHCG、ROC曲线下与坐标轴围成的面积（AUC）值最大，为0.684］及与临床资料的相关性分析结果表明，lncRNA GIHCG表达与胆管癌患者淋巴结转移具有明显相关性，n P<0.001。lncRNA GIHCG在胆管癌组织中的表达显著升高，与肿瘤大小和淋巴结转移密切相关。Transwell实验结果表明，lncRNA GIHCG可促进胆管癌细胞的迁移。n 结论:lncRNA GIHCG的表达水平在胆管癌组织中显著升高，且与患者生存、淋巴结转移密切相关，有望成为新的胆管癌诊断或治疗分子标志物。“,”Objective:To screen long non-coding RNA (lncRNA) related to the prognosis of cholangiocarcinoma patients, detect its expression in cholangiocarcinoma tissue, and analyze its clinical significance by analyzing The Cancer Genome Atlas (TCGA) database.Methods:Using limma package, survival package, and survival receiver operating characteristic curve (ROC) package of R software to analyze the data of cholangiocarcinoma in TCGA and screen the differentially expressed lncRNAs related to patient survival. Real-time PCR and Fish were used to detect the expression of lncRNA and analyze its correlation with the clinical characteristics of patients. Small interfering RNA was used to knock down the expression of lncRNA GIHCG, and its effect on the migration ability of cholangiocarcinoma cell lines was detected by Transwell.Results:The results of the comprehensive analysis of survival, ROC, and correlation analysis with clinical data showed that lncRNA GIHCG has a significant correlation with lymph node metastasis in patients with cholangiocarcinoma. The expression of lncRNA GIHCG in cholangiocarcinoma tissue is significantly increased, closely related to tumor size and lymph node metastasis. Transwell results showed that lncRNA GIHCG could promote the migration of cholangiocarcinoma cells.Conclusion:The expression of lncRNA GIHCG is significantly increased in cholangiocarcinoma tissues and is closely related to patient survival and lymph node metastasis. It is expected to become a new molecular marker for diagnosing or treating cholangiocarcinoma.